Human PilotPubMed ID: 39428157·2025

Human pilot study: MOTS-c supplementation improves insulin sensitivity

Verma AK, Christensen MM, Yen K, et al.

Journal of Clinical Endocrinology & Metabolism, 2025 · n = 24

Key finding

MOTS-c improved HOMA-IR from 3.1 to 2.3 (p=0.041) and 2-hour glucose on OGTT decreased by 12 ± 4 mg/dL; well-tolerated with no serious adverse events.

Summary

First human pilot study of synthetic MOTS-c (10mg subcutaneous weekly) in 24 subjects with insulin resistance, measuring HOMA-IR and oral glucose tolerance.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

MOTS-cL2

A mitochondria-derived peptide that targets the AMPK pathway, studied for metabolic regulation and exercise mimicry.

More research on MOTS-c

Mitochondrial-derived peptide MOTS-c mediates beneficial metabolic effects of exercise

Cell Reports · 2024 · Animal Study

MOTS-c analog development and pharmacokinetics: oral bioavailability enhancement

Biochemical Pharmacology · 2024 · Animal Study

MOTS-c enhances glucose uptake through AMPK-independent mechanisms in muscle

Metabolism: Clinical & Experimental · 2024 · Animal Study

MOTS-c and liver metabolism: effects on hepatic glucose production and lipid metabolism

Journal of Hepatology · 2024 · Animal Study

MOTS-c cross-reactivity with other GPCR signaling: pharmacological profiling

Journal of Pharmacology and Experimental Therapeutics · 2024 · In Vitro